BIAL ANNOUNCES THE PURCHASE OF ALL THE LYSOSOMAL THERAPEUTICS ASSETS AND CREATES BIAL BIOTECH INVESTMENTS, INC., A CENTER OF EXCELLENCE IN PARKINSON’S DISEASE IN CAMBRIDGE, MASS. USA.
Employees: 11-50
Total raised: $24.8M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.02.2015 | Series A | $20M | - |
| 12.05.2014 | Seed | $4.8M | - |
Mentions in press and media 6
| Date | Title | Description |
| 03.02.2015 | Lysosomal Therapeutics Inks $20M in Series A | CAMBRIDGE, MA, Company leveraging its expertise in lysosomal biology to develop novel small molecules for use in the treatment of neurodegenerative diseases, has raised $20M in Series A financing. >> Click here for more funding dat... |
| 03.02.2015 | Lysosomal Therapeutics Raises $20M in Series A Financing | Lysosomal Therapeutics Inc. (LTI), a Cambridge, Mass.-based developer of novel small molecules for use in the treatment of neurodegenerative diseases, raised $20m in Series A financing. Backers included existing investors Atlas Venture, Hat... |
| 03.02.2015 | Lysosomal Therapeutics raises $20M Series A from Sanofi, Lilly and Roche for Parkinson’s drug | Promoted Clinical Care Capacity Planning Learn how to manage clinical care capacity more efficiently during uncertain times. SAP Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recov... |
| 12.05.2014 | Lysosomal Therapeutics Inks $4.8M in Seed Funding | CAMBRIDGE, MA, Company leveraging its expertise in lysosomal biology to develop novel small molecules for use in the treatment of neurodegenerative diseases, announced today it has raised $4.8 million in seed funding. >> Click here... |
| 12.05.2014 | Lysosomal Therapeutics Raises $4.8M in Seed Funding | Lysosomal Therapeutics Inc., a Cambridge, Mass.-based developer of novel small molecules for use in the treatment of neurodegenerative diseases, raised $4.8m in seed funding. The round was led by Atlas Venture with participation from Hatter... |
| - | Lysosomal Therapeutics raises $20M Series A from Sanofi, Lilly and Roche for Parkinson’s drug | Cambridge biotech Lysosomal Therapeutics just raised a whopping $20 million Series A for its small molecule Parkinson’s disease treatment, with backing from the venture arms of several big pharma – Sanofi, Lilly and Roche. The company will ... |